This 2016 review by Reed-Maldonado and Lue examines the application of stem cell (SC) therapy for erectile dysfunction (ED). The authors discuss various types of stem cells, including adipose-derived, bone marrow-derived, and umbilical cord-derived stem cells, and their potential mechanisms in treating ED. The review highlights four clinical trials where
This 2020 study evaluated the safety and efficacy of autologous bone marrow-derived stem cells (BMSCs) in 32 eyes from patients aged 69–90 with dry age-related macular degeneration (AMD). BMSCs were administered via retrobulbar, subtenons, intravitreal, subretinal, and intravenous routes. After treatment, 63% of eyes showed improvement in visual acuity, 34%
The SCOTS and SCOTS2 trials evaluated the safety and efficacy of autologous bone marrow-derived stem cells (BMSCs) in 34 eyes from patients with Stargardt Disease. BMSCs were administered via retrobulbar, subtenons, intravitreal, subretinal, and intravenous routes. After one year, 61.8% of eyes showed visual improvement, 23.5% remained stable, and 14.7%
This 2021 systematic review evaluated clinical studies on stem cell therapy (SCT) for erectile dysfunction (ED), highlighting its potential as a regenerative treatment. Various stem cell types—adipose-derived (ADSC), bone marrow-derived (BMSC), umbilical cord, and placental—have been administered primarily via intracavernosal injection. Clinical trials reported improvements in erectile function, with some
This study reports on the SCOTS trial, which utilized autologous bone marrow-derived stem cells (BMSCs) to treat patients with Leber’s Hereditary Optic Neuropathy (LHON). Treatment methods included retrobulbar, subtenon, intravitreal, intra-optic nerve, subretinal, and intravenous injections of BMSCs. Patients experienced visual acuity improvements, with gains up to 35 letters on
